2023-06-05 12:30:00 CEST

2023-06-05 12:30:07 CEST


REGULATED INFORMATION

English
Optomed Oyj - Major shareholder announcements

Disclosure under Chapter 9, Section 10 of the Securities Markets Act regarding change in holdings


Optomed PlcStock Exchange Release5 June 2023 at 13.30, Helsinki

Disclosure under Chapter 9, Section 10 of the Securities Markets Act regarding
change in holdings

Optomed Plc (“Optomed” or the “Company”) has received a notification in
accordance with the Chapter 9, Section 5 of the Finnish Securities Markets Act
(as amended, the “SMA”) from Cenova Capital (“Notifier”). According to the
notification, the total holdings in Optomed shares and votes held by Notifier
through its funds (Shanghai Cenova Innovation Venture Fund (Limited
Partnership), Alnair Investment and Cenova China Healthcare Fund IV, L.P.) has
decreased to 9.96 per cent of all of the registered shares in Optomed on 2 June
2023.

The total number of the Company's registered shares amounts to 16,541,355
shares. Each share entitles to one vote.

The total position of Notifier subject to the notification:

+----------------+----------+------------------------------------+---------+
|                |% of      |% of shares and voting rights       |Total of |
|                |shares and|through financial instruments (total|both in %|
|                |voting    |of B)                               |(A+B)    |
|                |rights    |                                    |         |
|                |(total    |                                    |         |
|                |of A)     |                                    |         |
+----------------+----------+------------------------------------+---------+
|Resulting       |9.96 %    |-                                   |9.96 %   |
|situation on the|          |                                    |         |
|date on         |          |                                    |         |
|which threshold |          |                                    |         |
|was crossed or  |          |                                    |         |
|reached         |          |                                    |         |
+----------------+----------+------------------------------------+---------+
|Position of     |14.36 %   |-                                   |14.36 %  |
|previous        |          |                                    |         |
|notification    |          |                                    |         |
|(if applicable) |          |                                    |         |
+----------------+----------+------------------------------------+---------+

Notified details of the resulting situation on the date on which the threshold
was crossed or reached:

A: Shares and voting rights

+------------+-----------------+----------------+-----------------+-----------+
|Class/type  |Number of shares and voting rights|% of shares and voting rights|
|of shares   |                                  |                             |
|            |                                  |                             |
|ISIN code   |                                  |                             |
+------------+-----------------+----------------+-----------------+-----------+
|Direct      |Indirect         |Direct          |Indirect         |
|(SMA 9:5)   |(SMA 9:6 and 9:7)|(SMA 9:5)       |(SMA 9:6 and 9:7)|
+------------+-----------------+----------------+-----------------+-----------+
|FI4000410881|1,647,771        |-               |9.96 %           |-          |
+------------+-----------------+----------------+-----------------+-----------+
|SUBTOTAL A  |2,211,664                         |9.96 %                       |
+------------+-----------------+----------------+-----------------+-----------+

Information in relation to the person subject to the notification obligation as
contained in the notification

The complete chain of controlled undertakings through which the shares, voting
rights and/or the financial instruments are effectively held starting with the
ultimate controlling natural person or legal entity:

+-----------------+----------------+-----------------------------+------------+
|Name             |% of shares and |% of shares and voting rights|Total of    |
|                 |voting rights   |through financial instruments|both        |
+-----------------+----------------+-----------------------------+------------+
|Cenova China     |0% of shares and|-                            |0% of shares|
|Healthcare GP IV |100% voting     |                             |and 100%    |
|Limited          |rights          |                             |voting      |
|                 |                |                             |rights of   |
|                 |                |                             |Cenova China|
|                 |                |                             |Healthcare  |
|                 |                |                             |Fund IV, L.P|
+-----------------+----------------+-----------------------------+------------+
|Shanghai Cenova  |1% of shares and|-                            |1% of shares|
|Bioventure Equity|100% voting     |                             |and 100%    |
|Investment Fund  |rights          |                             |voting      |
|Management       |                |                             |rights of   |
|Enterprise       |                |                             |Shanghai    |
|                 |                |                             |Cenova      |
|                 |                |                             |Innovation  |
|                 |                |                             |Venture Fund|
|                 |                |                             |(Limited    |
|                 |                |                             |Partnership)|
+-----------------+----------------+-----------------------------+------------+
|Shanghai Cenova  |100%            |-                            |100% of     |
|Innovation       |                |                             |Alnair      |
|Venture          |                |                             |Investment  |
|Fund (Limited    |                |                             |            |
|Partnership)     |                |                             |            |
+-----------------+----------------+-----------------------------+------------+

Further enquiries

Sakari Knuutti, CFO, Optomed Plc, sakari.knuutti@optomed.com

www.optomed.com

Optomed in Brief

Optomed is a Finnish medical technology company and one of the leading providers
of handheld fundus cameras. Optomed combines handheld screening devices fundus
cameras with software and artificial intelligence with the aim to transform the
diagnostic process of blinding eye-diseases such as rapidly increasing diabetic
retinopathy. In its business Optomed focuses on eye-screening devices and
software solutions related R&D in Finland and sales through different channels
in over 60 countries.